Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer [ELCC 2021 Virtual Press Release]
LUGANO, Switzerland; DENVER, CO, USA - Clinical activity with a second drug inhibiting KRAS G12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC)...
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Source : https://www.sciencedirect.com/science/article/pii/S266637912030241X
KRAS, an oncogenic driver in lung cancer, is known as an "undruggable" target Different strategies are under investigation to indirectly and directly target KRAS Clinical trials of small-molecule inhibitors report...
The Prevalence and Concurrent Pathogenic Mutations of KRAS G12C in Northeast Chinese Non-small-cell Lung Cancer Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33758543/
1 Medical Oncology Translational Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, People's Republic of China. 2 Department of Medical Thoracic...
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33753749/
Mutational activation of KRAS promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations. Although epidemiological...
60-Year-Old Professor with Increasing Fatigue
A 60-year-old immunology professor presents complaining of increasing fatigue over the past 3-to-4 months. She had a cough for a couple of weeks that resolved on its own. She experienced a few night sweats.
Her medical history is unremarkable. She experiences palpitations related to paroxysmal...